Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Molnupiravir reduces severe illness and death, but it must be started within days after developing symptoms.
Another vaccine, from Novavax, was 89% effective in a U.K. trial, but both were less potent against the South African coronavirus mutation.
Keytruda plus chemotherapy reduced the risk of disease progression or death by 35% compared with chemotherapy alone in certain people.
Couric has partnered with Merck to produce a web series about being treated for cancer during the pandemic.
The American Red Cross and the American Cancer Society come together to encourage people to #GiveBloodtoGiveTime.
Enfortumab vedotin plus Keytruda yielded a confirmed response in 71% of participants.
Adding immunotherapy to preoperative chemotherapy increased the likelihood of complete remission.
New immunotherapy option approved for uncommon, aggressive type of lung cancer.
First-line immunotherapy improved overall survival by around 20% to 40%, depending on PD-L1 level.
The immunotherapy led to an improvement in survival for people with gastric or gastroesophageal junction cancers with a high PD-L1 level.
The immunotherapy drug shows the most benefit for newly treated people with tumors that test positive for the PD-L1 biomarker.
Join the Melanoma Research Alliance and share your message with the newly launched With Love, Me program.
Immunotherapy and targeted therapy combo is now approved for first-time treatment of advanced renal cell carcinoma.
Stop me if you’ve heard this one before.
First-line immunotherapy combo delayed disease progression and reduced the risk of death by nearly half.
A second immunotherapy option is now available for hepatocellular carcinoma.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.